Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis (RELEASE MSS3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04203498
Recruitment Status : Recruiting
First Posted : December 18, 2019
Last Update Posted : March 15, 2021
Sponsor:
Information provided by (Responsible Party):
GW Pharmaceuticals Ltd.

Brief Summary:
This trial is being conducted to demonstrate the efficacy of nabiximols, compared with placebo, when added to standard of care, in the treatment of muscle spasms associated with multiple sclerosis (MS).

Condition or disease Intervention/treatment Phase
Multiple Sclerosis (MS) Drug: Nabiximols Drug: Placebo Phase 3

Detailed Description:

This multicenter, double-blind, placebo-controlled trial includes a 28-day Baseline period, a 12-week treatment period (comprising a 2-week titration phase and a 10-week maintenance phase), and 2-week follow-up period.

Eligible participants will enter the 28-day baseline period. During baseline, participants will maintain their optimized oral MS antispasticity medication regimen and record spasm count using an electronic daily diary. At screening (Day 1), eligible participants will be randomized to either nabiximols or placebo in a 1:1 ratio.

Participants will be advised to titrate the investigational medicinal product (IMP), beginning with 1 spray/day, to an optimized dose or to a maximum of 12 sprays/day over the first 14 days of treatment. Participants may leave a gap between sprays of approximately 15 minutes. Participants should continue at the same dose level achieved at the end of the titration phase ±1 spray divided into a morning dose and an evening dose for the remainder of the treatment period.

Daily spasm count, the participant's symptom experiences, clinician's assessment of spasticity, functional outcomes, health-related quality of life, changes in mood, safety, tolerability, and pharmacokinetics will be evaluated during the treatment period.

Participants who complete the trial will participate for a total of approximately 18 weeks (127 days), including the 28-day baseline period. Participants will have a maximum duration of 85 (±7) days on IMP treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 446 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy and Safety of Nabiximols Oromucosal Spray as Add-on Therapy in Patients With Spasticity Due to Multiple Sclerosis
Actual Study Start Date : October 1, 2020
Estimated Primary Completion Date : October 5, 2022
Estimated Study Completion Date : November 2, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Nabiximols Drug: Nabiximols
Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
Other Names:
  • GW-1000-02
  • Sativex

Placebo Comparator: Placebo Drug: Placebo
Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 microliters (μL) containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.




Primary Outcome Measures :
  1. Change from Baseline in the Average Daily Spasm Count (from Days 57 to 84 Compared to the Average Daily Spasm Count for the Baseline Period) [ Time Frame: Baseline, Day 84 ]

Secondary Outcome Measures :
  1. Change From Baseline in The Multiple Sclerosis Spasticity Scale (MSSS-88) Total Score at Day 85 [ Time Frame: Baseline, Day 85 ]
  2. Number of Participants with Treatment-emergent Adverse Events [ Time Frame: Baseline through Day 99 ]
  3. Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory Test Values at Days 29 and 85 [ Time Frame: Baseline, Days 29 and 85 ]
  4. Number of Participants with Clinically Significant Changes from Baseline in Vital Sign Values at Days 15, 29, 57, 85, and 99 [ Time Frame: Baseline, Days 15, 29, 57, 85, and 99 ]
  5. Number of Participants with Clinically Significant Changes from Baseline in Physical Examination Values at Day 85 [ Time Frame: Baseline, Day 85 ]
  6. Number of Participants with Clinically Significant Changes from Baseline in 12-lead Electrocardiogram (ECG) Values at Days 29 and 85 [ Time Frame: Baseline, Days 29 and 85 ]
  7. Mean Columbia-Suicide Severity Rating Scale (C-SSRS) Score at Days 15, 29, 57, and 85 [ Time Frame: Days 15, 29, 57, and 85 ]
  8. Plasma Concentrations for Tetrahydrocannabinol (THC), Cannabidiol (CBD), and Relevant Metabolites at Days 1 (Predose), 15, 29, 57, and 85 [ Time Frame: Days 1, 15, 29, 57, and 85 ]
    Sparse pharmacokinetic (PK) sampling option, blood samples will be taken as follows: Day 1, predose; Days 15, 29, 57, and 85, any time during the visit. Semi-intensive PK sampling option, blood samples will be taken as follows: Day 1, predose. At 1 visit (either Days 15, 29, or 57, 1 sample predose (i.e., prior to administration of investigational medicainal product [IMP] at the investigational site), 1 sample between 2 and 3 hours postdose, 1 sample between 4 and 6 hours postdose, and 1 sample between 6 and 8 hours postdose



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Criteria at screening:

  1. Participant is male or female aged 18 years or above.
  2. Participant has had a diagnosis with any disease subtype of multiple sclerosis (MS), by revised 2017 McDonald criteria, for at least 12 months prior to screening and is expected to remain stable for the duration of the trial.
  3. Participant has had treatment with at least 1 optimized oral antispasticity therapy prior to Visit 1 that must include either oral baclofen or oral tizanidine (monotherapy or combination therapy).
  4. Participant is currently receiving optimized treatment with at least 1 oral antispasticity medication (baclofen, tizanidine, and/or dantrolene) and has been stable for at least 30 days prior to screening.
  5. If the participant is currently receiving an approved MS disease-modifying therapy, it must be at a stable dose for at least 3 months prior to screening and is expected to remain stable for the duration of the trial.

Exclusion Criteria:

  1. Participant has any concomitant disease or disorder that has spasticity-like symptoms or that may influence the participant's level of spasticity.
  2. Participant has had a relapse of MS within the 60 days prior to screening (Visit 1).
  3. Participant is currently using or has used cannabis or a cannabinoid-derived product for medicinal or recreational use (within 30 days of screening) and is unwilling to abstain for the duration of the trial.
  4. Participant is currently using botulinum toxin injection for the relief of spasticity (within 6 months of screening) and is unwilling to abstain for the duration of the trial.
  5. Participant has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the IMP.
  6. Participant is male and fertile unless willing to ensure that he uses male contraception or remains sexually abstinent during the trial and for 3 months thereafter.
  7. Participant is female and of childbearing potential unless willing to ensure that she uses a highly effective method of birth control during the trial and for 3 months thereafter.
  8. Participant is female and pregnant, lactating, or planning pregnancy during the course of the trial or within 3 months thereafter.
  9. Participant has received an IMP within the 30 days prior to screening.
  10. Participant has a history of severe psychiatric disorder that may be exacerbated by the use of a cannabinoid-containing product.
  11. Participant has any known or suspected history of alcohol or substance abuse (including opiate abuse) or dependence within 1 year prior to screening.
  12. Participant is currently taking drugs that are solely metabolized by UGT1A9 and UGT2B7
  13. Participant is currently taking strong currently taking strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital, St John's Wort)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04203498


Contacts
Layout table for location contacts
Contact: Medical Enquiries 1-833-424-6724 medinfo@gbio.com

Locations
Layout table for location information
Czechia
Poliklinika Choceň Recruiting
Choceň, Czechia
Nemocnice Jihlava Recruiting
Jihlava, Czechia
Krajská Zdravotní - Nemocnice Teplice Recruiting
Teplice, Czechia
Poland
Centrum Medyczne Neuromed - Ośrodek Badań Klinicznych Recruiting
Bydgoszcz, Poland
RESMEDICA Poradnia Neurologiczna Recruiting
Kielce, Poland
Wromedica Centrum Zdrowia Recruiting
Wrocław, Poland
Wielospecjalistyczne Centrum Medyczne Ibismed Recruiting
Zabrze, Poland
Sponsors and Collaborators
GW Pharmaceuticals Ltd.
Layout table for additonal information
Responsible Party: GW Pharmaceuticals Ltd.
ClinicalTrials.gov Identifier: NCT04203498    
Other Study ID Numbers: GWSP18023
2019-002623-14 ( EudraCT Number )
First Posted: December 18, 2019    Key Record Dates
Last Update Posted: March 15, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by GW Pharmaceuticals Ltd.:
Spasticity
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscle Spasticity
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Muscular Diseases
Musculoskeletal Diseases
Muscle Hypertonia
Neuromuscular Manifestations
Neurologic Manifestations
Nabiximols
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs